All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Liqenza 32mg Oral Solution 150ml
Prescription Required
Salt Composition : Enzalutamide
Manufacturer : ZYDUS CADILA
Origin of Medicine : India
1 Bottle(s) Of 150ml
Introduction to Liqenza 32mg Oral Solution 150ml
Liqenza 32mg Oral Solution 150ml contains the active compound enzalutamide which belongs to the class of medications called androgen receptor inhibitors. It is used to treat men with prostate cancer. It is suitable for treatment in men with high testosterone, where the treatments (hormonal therapy or testosterone-lowering surgery) that reduce testosterone no longer totally cure the malignancy. It is also suitable for treatment in metastatic cases where the cancer has spread from the prostate to other parts and reacts to hormone therapy or surgery to reduce testosterone levels. It is also used in cases of Prostate cancer that is responsive to castration( surgical removal of testicles) but is not metastatic, with a high chance of metastasis and a biochemical recurrence.
It is not recommended to take Liqenza 32mg Oral Solution 150ml if you are allergic to active compounds or any other ingredients of this medicine. It is not recommended for use in children and adolescents below the age of 18. Men are advised to use effective contraceptive methods during the therapy and 3 months after the treatment since it has the ability to harm the developing foetus. Inform your doctor if you are pregnant or planning to get pregnant to know about effective contraceptive methods. It is recommended to test your bone density during the treatment.
Before initiating the treatment, inform your physician if you have any infections, kidney, heart or liver problems. Patients who have ischemic heart disease are closely monitored for risk factors. Inform your doctor right away if you experience a seizure, headache that is getting worse, disorientation, blindness, or any other vision issues. It is necessary to inform your physician about all the medicines, over the counter drugs, vitamin and herbal supplements you are taking before the start of therapy.
Uses of Liqenza 32mg Oral Solution 150ml
- Prostate cancer resistant to other treatments
- Metastatic prostate cancer reacts to hormone therapy or surgery to reduce testosterone levels
- Non-metastatic prostate cancer with a high chance of spread and recurrence.
Therapeutic Effects of Liqenza 32mg Oral Solution 150ml
Liqenza 32mg Oral Solution 150ml medicine acts by blocking the activity of androgens hormone (such as testosterone) by binding with androgen receptors. Liqenza 32mg Oral Solution 150ml prevents the Androgen receptor from moving to its new site, which further lowers AR-mediated transcriptional activity and stops the growth of tumor cells. Liqenza 32mg Oral Solution 150ml inhibits the AR complex's ability to bind to DNA, which stops the transcriptional activation of AR target genes. As a result, it reduces testosterone levels and halts the growth and division of prostate cancer cells.
Interaction of Liqenza 32mg Oral Solution 150ml with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Liqenza 32mg Oral Solution 150ml and reduce effectiveness by causing undesirable side effects.
More Information about Liqenza 32mg Oral Solution 150ml
- Liqenza 32mg Oral Solution 150ml should be stored at room temperature between 20°C and 25°C (68°F and 77°F).
- It should be kept dry and protected from light and moisture.
- The capsules should be kept in the original container with the cap tightly closed..
- Keep it out of reach from children and pets.
- It is important to get the dose at the scheduled time. If you missed the schedule, contact your doctor and reschedule the dose.
How to consume Liqenza 32mg Oral Solution 150ml
Liqenza 32mg Oral Solution 150ml is usually taken orally, with or without food. The capsules should be swallowed whole with a glass of water and not crushed, chewed or broken.
The dosage and frequency of Liqenza 32mg Oral Solution 150ml will depend on various factors, including the patient's age, weight, overall health, and the type and stage of cancer being treated. It's important to follow the dosing instructions provided by a healthcare provider, and not to adjust the dosage or frequency without consulting with them first. Pregnant or potentially pregnant women shouldn't handle broken or damaged Xtandi tablets without wearing gloves or other protective gear.
If a dose is missed, it should be taken as soon as possible unless it's within 6 hours of the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. It's important not to take a double dose of abemaciclib to make up for a missed dose.
Safety Advices for Liqenza 32mg Oral Solution 150ml
Pregnancy
Liqenza 32mg Oral Solution 150ml is not indicated for use in women. It is unsafe for pregnant women as it may cause foetal harm. It can cause damage to a developing baby if taken during pregnancy. It is important to use effective contraception.
Breast Feeding
Liqenza 32mg Oral Solution 150ml is not recommended during breastfeeding, as it is unknown if it is excreted in human milk. Because of the potential risk to the infant, breastfeeding is not recommended.
Lungs
It is unknown whether Liqenza 32mg Oral Solution 150ml is safe for patients with lung problems. Inform your physician if you have any lung disease before starting the treatment. Contact your doctor if you experience any lung-related symptoms.
Liver
Inform your physician about any underlying liver disorders before taking Liqenza 32mg Oral Solution 150ml, as this medication should be used cautiously in liver disease patients.
Alcohol
It is typically advised that patients taking Liqenza 32mg Oral Solution 150ml avoid or consume alcohol in moderation since it can worsen any liver-related adverse effects of drug and raise the risk of liver damage.
Driving
Liqenza 32mg Oral Solution 150ml may cause side effects such as seizures, dizziness, or blurred vision that can impair a patient's ability to drive or operate machinery safely. It possesses a minimal impact on one's capacity to operate and drive machinery.If a patient experiences any side effects that affect their ability to drive or operate machinery safely while taking Liqenza 32mg Oral Solution 150ml, they should avoid these activities and seek medical advice.
Side Effects of Liqenza 32mg Oral Solution 150ml
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Common
- Tiredness
- Fall
- Hot flushes
- High blood pressure
- Headache
- Feeling anxious
- Dry skin
- Itching
- Difficult in remembering
- Restlessness
Serious:
- Posterior Reversible Encephalopathy Syndrome (PRES)
- Blockage of the arteries (ischemic heart disease)
- Enlargement of breast in men (gynaecomastia)
- Broken bones
Word of Advice
If you have prescribed Liqenza 32mg Oral Solution 150ml, it is important to follow the instructions provided by your healthcare provider and to report any side effects or concerns promptly. It is advised not to consume grape juice during the treatment. Stay hydrated by consuming lots of liquids, particularly if you get diarrhea when using Liqenza 32mg Oral Solution 150ml. It's critical to maintain a sufficient fluid intake because dehydration can exacerbate symptoms such as diarrhea and other gastrointestinal disorders. Even if you feel better or see a change in your symptoms, you should still talk to your doctor before stopping Liqenza 32mg Oral Solution 150ml. It is recommended to monitor your blood counts and bone density at regular intervals. It is not advised for women, particularly for those who are nursing or pregnant. Notify your physician if you experience frequent urges to urinate, blood in your urine, or digestive issues. Inquire with your physician if you get discomfort in the bladder or colon, as the medication may result in bladder or colon cancer as a side effect.
Remember to attend all scheduled appointments and follow-up visits with your healthcare provider to ensure your treatment is effective and any side effects are managed appropriately. With proper monitoring and management, Liqenza 32mg Oral Solution 150ml can be an effective treatment option for prostate cancer.
FAQs
Q 1. Can I take Liqenza 32mg Oral Solution 150ml if I have a liver problem?
It is not recommended for liver patients; speak with your doctor before using the Liqenza 32mg Oral Solution 150ml if you have any liver problems.
Q 2. Can I take Liqenza 32mg Oral Solution 150ml if I am pregnant?
No, Liqenza 32mg Oral Solution 150ml is not recommended for pregnant women. It may be contraindicated for pregnant women, and it might cause harm to the foetus.
Q 3. Should I monitor any parameters while taking Liqenza 32mg Oral Solution 150ml?
Your doctor will advise you to check your blood pressure and hemoglobin level and bone density because Liqenza 32mg Oral Solution 150ml may cause low blood pressure and anemia as a side effect.
Q 4. What are the precautions I need to take while taking Liqenza 32mg Oral Solution 150ml?
Inform your doctor if you have any history of liver, kidney or heart problem (irregular heart beat) and seizure or cancer (other than prostate cancer). Inform your doctor if you have gastrointestinal problems or blood in urine or frequent urge for urination.
Q 5. Can I take Liqenza 32mg Oral Solution 150ml if I have a seizure?
No, it is not recommended for patients with seizures. It may be contraindicated for a person with seizure.
Fact Box of Liqenza 32mg Oral Solution 150ml
Molecule name: Enzalutamide | Therapeutic class: Anti-androgen |
Pharmacological class: Androgen receptor antagonists
| Indications:
|
Dosage form: Capsules | Habit forming: No |
References
- Astellas Pharma Europe B.V, Electronics Medicines Compendium(EMC), [ Revised on December 2022] [ Accessed on 30/03/2024], https://www.medicines.org.uk/emc/files/pil.10318.pdf
- Astellas Pharma US Inc, United States Food and Drug Administration (US FDA), [ Revised on January 2022] [ Accessed on 30/03/2024], https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203415s018,213674s005lbl.pdf
- Astellas Pharma US, Inc, [Revised on November 2023], [Accessed on 30/03/2024], https://www.astellas.us/docs/12A005-ENZ-WPI.PDF
- KD Tripathi, Essentials of Medical Pharmacology, Adrenergic system and drugs, 7th edition, 2013, 134.
Disclaimer